Shionogi Aktie
13,30EUR | 0,00EUR | 0,00% |
WKN: 855648 / ISIN: JP3347200002
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 78,42 |
Sumitomo Life Insurance Co. | 6,27 |
Nomura Asset Management Co., Ltd. | 6,21 |
Shionogi & Co., Ltd. | 3,37 |
Sumitomo Mitsui Banking Pension Fund | 3,20 |
Sumitomo Mitsui Trust Asset Management Co., Ltd. | 3,05 |
Nikko Asset Management Co., Ltd. | 3,01 |
BlackRock Fund Advisors | 3,01 |
Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 2,98 |
Nippon Life Insurance Co. | 2,84 |
Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 2,18 |
Ping An Insurance (Group) Co. of China Ltd. | 2,14 |
BlackRock Japan Co. Ltd. | 2,08 |
Nikko Exchange Traded Index Fund 225 | 1,44 |
Daiwa Asset iFreeETF NIKKEI 225 (Yearly Dividend Type) (1320) | 1,35 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 5 222 | 5 485 | 5 693 | 5 680 | 4 959 |
Umsatz pro Mitarbeiter in Mio. EUR | 63,84 | 54,18 | 58,87 | 75,12 | 87,74 |
Bilanz (in Mio. JPY) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 516 026 | 556 238 | 659 205 | 784 192 | 784 205 |
Summe Anlagevermögen | 355 500 | 442 754 | 491 396 | 527 608 | 632 713 |
Summe Aktiva | 871 526 | 998 992 | 1 150 601 | 1 311 800 | 1 416 918 |
Bilanz (in Mio. JPY) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 106 913 | 134 438 | 157 314 | 189 919 | 164 354 |
Summe Eigenkapital | 764 611 | 864 550 | 993 285 | 1 121 878 | 1 252 562 |
Summe Passiva | 871 524 | 998 988 | 1 150 599 | 1 311 797 | 1 416 916 |
Adresse
3-1-8 Dosho-machi, 541-0045 Osaka | |
Telefon | +81 (6) 6202-2161 |
Fax | +81 (6) 6229-9596 |
Internet | http://www.shionogi.co.jp |
Management
Akira Okamoto
Auditor |
Fumi Takatsuki
Independent Outside Director |
Hiroshi Ozaki
Independent Outside Director |
Isao Teshirogi
Chairman, President & Chief Executive Officer |
John Keller
Senior Executive Officer, Head-R&D |
Kazuhiro Hatanaka
Senior Executive Officer & Head-Business Strategy |
Keiichi Ando
Independent Outside Director |
Kohji Hanasaki
Senior Executive Officer & Head-Supply Chain |
Masako Kudo
Manager-Finance & Accounting |
Noriyuki Kishida
Auditor |
Takaoki Fujiwara
Independent Outside Director |
Takeshi Shiota
Executive Officer & Head-Quality Assurance |
Takuko Sawada
Vice Chairman |
Yasuetsu Imune
General Manager-Drug Discovery Research |